✦ LIBER ✦

Economic evaluation of a randomized controlled trial of ultrasound therapy for hard-to-heal venous leg ulcers

✍ Scribed by L.-H. Chuang; M. O. Soares; J. M. Watson; J. M. Bland; N. Cullum; C. Iglesias; A. R. Kang'ombe; D. Torgerson; E. A. Nelson; on behalf of the VenUS III team

Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 348 KB
Volume: 98
Category: Article
ISSN: 0007-1323
DOI: 10.1002/bjs.7501

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Economic analysis of VenUS I, a randomiz

Economic analysis of VenUS I, a randomized trial of two bandages for treating venous leg ulcers

✍ C. P. Iglesias; E. A. Nelson; N. Cullum; D. J. Torgerson 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 339 KB 👁 2 views

Randomized controlled trial and cost-eff

Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial)

✍ Professor J. A. Michaels; B. Campbell; B. King; S. J. Palfreyman; P. Shackley; M 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Randomized controlled trial and cost-eff

Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial) (Br J Surg 2009; 96: 1147–1156)

✍ R. White; K. Cutting; K. Ousey; M. Butcher; D. Gray; M. Flanagan; J. Donnelly; C 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

Authors' reply: Randomized controlled tr

Authors' reply: Randomized controlled trial and cost-effectiveness analysis of silver-donating antimicrobial dressings for venous leg ulcers (VULCAN trial) (Br J Surg 2009; 96: 1147–1156)

✍ J. A. Michaels; W. B. Campbell; B. M. King; S. J. Palfreyman; P. Shackley; M. D. 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

The Editors welcome topical correspondence from readers relating to articles published in the Journal. Responses should be sent electronically via the BJS website (www.bjs.co.uk). All letters will be reviewed and, if approved, appear on the website. A selection of these will be edited and published

Rituximab for rheumatoid arthritis refra

Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

✍ Stanley B. Cohen; Paul Emery; Maria W. Greenwald; Maxime Dougados; Richard A. Fu 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 424 KB 👁 2 views